Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy

International Urology and Nephrology

Volumn 40, Issue 1, 2008, Pages 97-104

  Nelius, Thomas ^a,b   Klatte, Tobias ^b,c   Riese, Werner ^a   Filleur, Stephanie ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Docetaxel; Estramustine; Hormone refractory prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE SODIUM; ESTROGEN; GONADORELIN DERIVATIVE; PREDNISOLONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; PROSTATE CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; SYSTEMIC THERAPY; TRANSACTIVATION; VEIN THROMBOSIS;

ADENOCARCINOMA; AGED; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 41549125525     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9221-y     Document Type: Article

References (30)

1. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424
3. Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042
4. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
5. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109
6. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
7. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
8. Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343-3351
9. Noguchi K, Uemura H, Harada M et al (2001) Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist. Int J Clin Oncol 6:29-33
10. Fossa SD, Vaage S, Letocha H et al (2002) Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)-delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 36:34-39
11. Heidenreich A, Sommer F, Ohlmann CH et al (2004) Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101:948-956
12. Olbert PJ, Hegele A, Kraeuter P et al (2006) Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 17:993-996
13. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461-3467
14. Kreis W, Budman DR, Fetten J et al (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38
15. Hudes GR, Nathan F, Khater C et al (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156-3163
16. Pienta KJ, Redman B, Hussain M et al (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012
17. Nelius T, Reiher F, Lindenmeir T et al (2005) Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie 28:573-578
18. Kelly WK, Scher HI, Mazumdar M et al (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615
19. Sridhara R, Eisenberger MA, Sinibaldi VJ et al (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953
20. Petrylak DP, Scher HI, Li Z et al (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70:2870-2878
21. Roessner M, de Wit R, Tannock IF, Yateman N, Yao S-L, Yver A, Eisenberger MA, on behalf of the TAX 327 Investigators (2005) Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. J Clin Oncol 23:391: abstract 4554
22. Liu AY, True LD, LaTray L et al (1999) Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 40:192-199
23. van der Poel HG, Oosterhof GO, Schaafsma HE et al (1997) Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 49:652-657
24. Taplin ME, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and leukemia group B study 9663. J Clin Oncol 21:2673-2678
25. Brinkmann AO, Trapman J (2000) Prostate cancer schemes for androgen escape. Nat Med 6:628-629
26. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
27. Yeh S, Hu YC, Rahman M et al (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Nat Acad Sci U S A 97:11256-11261
28. Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: An overview. Endocr Rev 23:175-200
29. Godoy-Tundidor S, Hobisch A, Pfeil K et al (2002) Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8:2356-2361
30. Lu ML, Schneider MC, Zheng Y et al (2001) Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276:13442-13451